In vitro and in vivo anti-Helicobacter/Campylobacter activity of the aqueous extract of Enantia chlorantha

References

• Adamek RJ, Wegener M, Opferkuch W, Ruhl GN (1993): Successful Helicobacter pylori eradication: a systemic effect of antibiotics? Am J Gastroenterol 88: 792–793.
   PubMed Web of Science ®Google Scholar
• Adjanohoun JF, Aboubakar N, Dramane K, Ebot ME, Ekpere JA, Enow-Orock EG, Focho D, Gbile ZO, Kamanyi A, Kamsu Kom J, Keita A, Mbenkum T, Mbi CN, Nkongmeneck B, Satabie B, Sofowora A, Tamze V, Wirmum CK (1996): Traditional Medicine and Pharmacopoeia: Contribution to Ethnobotanic and Floristic Studies in Cameroon. Porto Novo, Benin, Organization of African Unity Scientific, Technical and Research Commission, Centre Nationale de Production des Manuels Scolaires, pp. 51: 63.
   Google Scholar
• Beales ILP (2001): Efficacy of Helicobacter pylori eradication therapies: A single centre observational study. BMC Gastroenterol 1: 1–9.
   PubMedGoogle Scholar
• Bloland PB, Ettling M, Meek S (2000): Combination therapy for malaria in Africa: hype or hope? Bull World Health Organ 78: 1378–1388.
   PubMed Web of Science ®Google Scholar
• Boda M, Tan PV, Nyasse B (2006): Rapid in vivo screening method for the evaluation of new anti-Helicobacter medicinal plant preparations. Afr J Trad CAM 3: 102–114.
   Google Scholar
• Cheesbrough M (2000): Microbiological tests. In: Cheesbrough M, ed., District Laboratory Practice in Tropical Countries, Part 2. Cambridge, Cambridge University Press, pp. 45–57.
   Google Scholar
• Courillon-Mallet A (2003): Quand et comment contrôler l’éradication de Helicobacter pylori après un traitement de première ligne? Gastroenterol Clin Biol 27: 473–477.
   PubMedGoogle Scholar
• Dunn BE, Cohen H, Blaser MJ (1997): Helicobacter pylori. Clin Microbiol Rev 10: 720–741.
   PubMed Web of Science ®Google Scholar
• Fauchere JL (1999): Bacteriological characteristics and diagnosis of Helicobacter pylori. Laborama 6: 5–8.
   Google Scholar
• Gisbert JP, Pajares JM (2003): Helicobacter pylori infection and perforated peptic ulcer prevalence of the infection and role of antimicrobial treatment. Helicobacter 8: 159–167.
   PubMed Web of Science ®Google Scholar
• Goddard AF, Jessa MJ, Barrett DA, Shaw PN, Idstrom JP, Cedeberg C, Spiller RC (1996): Effect of omeprazole on the distribution of metronidazole, amoxicillin and clarithromycin in human gastric juice. Gastroenterology 111: 358–367.
   PubMed Web of Science ®Google Scholar
• Hassan JI, Stark MR, Greenman J, Millar RM (1999): Activity of β-lactams and macrolides against Helicobacter pylori. Antimicrob Agents Chemother 43: 1387–1392.
   PubMed Web of Science ®Google Scholar
• Kato M, Yamaoka Y, Jae JK, Reddy R, Asaka M, Kashima K, Osato MS, El-Zaatari KAF, Graham YD, Kwon HD (2000): Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 44: 2214–2216.
   PubMed Web of Science ®Google Scholar
• Korwin JD (1999): Management of Helicobacter pylori-associated gastrointestinal disease. Laborama 6: 10–13.
   Google Scholar
• Kotecka BM, Rieckmann KH (1993): Chloroquine bioassay using malaria microcultures. Am J Trop Med Hyg 49: 460–464.
   PubMed Web of Science ®Google Scholar
• Lamouliatte H, Cayla R, Meyer M, Demotes-Mainard F, Vinco G, Quentin-Noury C, Cayla R, Zerbib F, Forestier S, de Mascarel A, Joubert-Collin M, Mégraud F (1991): Pharmacokinetics of oral and intravenous amoxicillin in human gastric mucosa. Ital J Gastroenterol 23 (Suppl 2): 109 (Abstr).
   Google Scholar
• Mahady GB, Pendland SL, Yun SG, Zhi-Zhen L, Stoia A (2003): Ginger (Zingiber officinale Roscoe) and the gingerols inhibit the growth of Cag A+ strains of Helicobacter pylori. Anticancer Res 23: 3699–3702.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, on behalf of the European Helicobacter pylori Study Group (EHPSG) (1997): Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report. Gut 41: 8–13.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Mégraud F, O’Moraion C, Hungin AP, Jones R, Axon A, Owen RJ, Costas M, Morgan DD, On SLW, Hill LR, Pearson AD, Morgan DR (2002): Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 report. Aliment Pharmacol Ther 16: 167–180.
   PubMed Web of Science ®Google Scholar
• Matysiak-Budnik T, Heyman M, Candalh C, Lethuaire D, Mégraud F (2002): In vitro transfer of clarithromycin and amoxicillin across the epithelial barrier: effect of Helicobacter pylori. J Antimicrob Chemother 50: 865–872.
   PubMed Web of Science ®Google Scholar
• Megraud F (1998): Antibiotic resistance in Helicobacter pylori infection. Br Med Bull 54: 207–216.
   PubMed Web of Science ®Google Scholar
• NCCLS (1999): Performance standards for antimicrobial susceptibility testing: Ninth Informational Supplement, NCCLS document M100-S9. Wayne, PA, National Committee for Clinical Laboratory Standards, pp. 120–126.
   Google Scholar
• Okamoto T, Yoshiyama H, Nakazawa1 T, In-Dal P, Myung-Woong C, Yanai H, Okita K, Shirai M (2002): A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. J Antimicrob Chemother 50: 849–856.
   PubMed Web of Science ®Google Scholar
• Petschow RW, Batema, RP, Lorna LF (1996): Susceptibility of Helicobacter pylori to bactericidal properties of medium-chain monoglycerides and free fatty acids. Antimicrob Agents Chemother 40: 302–306.
   PubMed Web of Science ®Google Scholar
• Schillio Y (1996): Helicobacter pylori et ulcère gastro-duodénal. Med Dig 22: 12–17.
   Google Scholar
• Sizemore CF, Quispe JD, Amsler KM, Modzelewski TC, Merrill JJ, Stevenson DA, Foster LA, Slee AM (2002): Effects of metronidazole, tetracycline, and bismuth-metronidazole-tetracycline triple therapy in the Helicobacter pylori SS1 mouse model after 1 day of dosing: development of a H. pylori lead selection model. Antimicrob Agents Chemother 46: 1435–1440.
   PubMed Web of Science ®Google Scholar
• Skirrow MB (1992): Campylobacter and Helicobacter enteritis gastritis. In: Greenwood D, Slack RCB, Peutherer JF, eds., Medical Microbiology, 14th ed. Edinburgh, Churchill Livingstone, pp. 353–361.
   Google Scholar
• Soll AH (1996): Consensus conference. Medical treatment of peptic ulcer disease. Practice guideline practice parameters? Committee of the American college of Gastroenterology. JAMA 275: 622–629.
   PubMed Web of Science ®Google Scholar
• Sterling TR, Alwood K, Gachuhi R, Coggin W, Blazes D, Bishai WR, Chaisson RE (1999): Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 13: 1899–1904.
   PubMed Web of Science ®Google Scholar
• Tan PV, Nyasse B, Enow-Orock GE, Wafo P, Forcha EA (2000): Prophylactic and healing properties of a new anti-ulcer compound from Enantia chlorantha in rats. Phytomedicine 7: 291–296.
   Web of Science ®Google Scholar
• Tan, PV, Nyasse B, Dimo T, Wafo P, Akahkuh BT (2002): Synergistic and potentiating effects of ranitidine and two new anti-ulcer compounds from Enantia chlorantha and Voacanga africana in experimental animal models. Pharmazie 57: 409–412.
   PubMed Web of Science ®Google Scholar
• Tan PV, Boda M, Sonke B, Etoa F-X, Nyasse B (2006): Susceptibility of Helicobacter and Campylobacter to crude extracts prepared from plants used in Cameroonian folk medicine. Pharmacologyonline 3: 877–891.
   Google Scholar
• Tan PV, Boda M, Enow-Orock GE, Etoa F-X, Bitolog P (2007): Acute and sub-acute toxicity profile of the aqueous stem bark extract of Enantia chlorantha Oliver (Annonaceae) in laboratory animals. Pharmacologyonline 1: 304–313.
   Google Scholar
• Vandamme P, De Ley J (1991): Proposal for a new family, Campylobacteraceae. Int J Syst Bacteriol 41: 451–455.
   Google Scholar
• Wafo P, Nyasse B, Fontaine, CA (1999): 7,8-dihydro-8-hydroxypalmatine (PAL) from Enantia chlorantha. Photochemistry 50: 279–281.
   Google Scholar